Efficacy on Pain Following a Procedure for Injecting Sclerotherapeutic Foam Into the Great Saphenous Vein

Exclusion Criteria

• •General:
• •Patient regularly taking analgesics or anti-inflammatories.
• •Patient suffering from a state or prior history of mental or psychiatric disorder or any other factor limiting aptitude to take an informed part and respect of the protocol; Patient suffering from chronic hepatopathology.
• •Renal insufficiency (clearance \< 60 ml/min. according to Cockcroft).
• •Patient suffering from a known evolving malignant pathology.
• •Patient suffering from decompensated cardiac or respiratory insufficiency.
• •Patient who is pregnant or breast-feeding.
• •Patient currently taking part in a clinical trial or who took part in a clinical trial during the month preceding inclusion.
• •Person deprived of liberty by a legal or administrative decision, Adult patient protected by the law, under legal protection or guardianship.
• •Linked to the pathology/product:
• •Patient suffering from LL pain other than vascular (sciatica, gonarthrosis, neuropathy, etc.)
• •Patient presenting contraindications for class III venous compression (20 to 36 mmHg)
• •Patient with a prior history of skin reactions following the use of venous compression products
• •Scheduling a procedure for endovenous injection other than into the great saphenous vein during the period of study of the leg, planned during the 2 months following SVG sclerosis.
• •Patient displaying post-thrombotic or primary anomalies of the deep vein network on the Echo-Doppler (less than 3 months before inclusion).
• •Patient suffering from arteriopathy of the lower limbs with a systolic pressure index at the ankle of \< 0.6